Zugmaier, G
Topp, M S
Alekar, S
Viardot, A
Horst, H-A
Neumann, S
Stelljes, M
Bargou, R C
Goebeler, M
Wessiepe, D
Degenhard, E
Gökbuget, N
Klinger, M
Article History
First Online: 5 September 2014
Competing interests
: G Zugmaier, E Degenhard and M Klinger are employees of Amgen Research (Munich) GmbH and stockholders in Amgen Inc. MS Topp has received honoraria as an invited speaker and consultant from Amgen Inc. S Alekar is an employee of and stockholder in Amgen Inc. A Viardot has consulted for Janssen-Cilag GmbH, Pfizer GmbH, and Gilead Sciences GmbH and received honoraria from Roche Pharmaceuticals and Pfizer GmbH. H-A Horst has received research funding from Amgen Inc. RC Bargou has consulted for and received honoraria from Amgen Inc.; he is listed as an inventor on patents related to blinatumomab but does not receive royalties from them. D Wessiepe is an employee of Metronomia GmbH and is a contractor to Amgen Inc. N Gökbuget has received research support and honoraria as invited speaker and consultant from Amgen Inc. The remaining authors declare no conflict of interest.